

~~Search~~ ~~Pub.~~ ~~Cont.~~

e) a conjugate of a carrier molecule selected from tetanus toxoid and diphtheria toxoid and a capsular polysaccharide of *Haemophilus influenzae* type B, wherein tetanus toxoid and diphtheria toxoid are adsorbed onto an aluminum salt before being mixed with the other components.

22. The method according to claim 21, wherein pertussis toxoid and filamentous hemagglutinin in purified form are adsorbed onto an aluminum salt before being mixed with the other components.

23. The method according to claim 21, wherein inactivated polio virus is mixed with the other components without being adsorbed onto an aluminum salt.

24. The method according to claim 21, wherein the aluminum salt is selected from a group consisting of aluminum hydroxide and aluminum phosphate.

25. The method according to claim 21, further comprising adding hepatitis B surface antigen adsorbed onto an aluminum salt.

26. The method according to claim 23, wherein mixing is conducted in the following order:

- adsorbing tetanus toxoid and diphtheria onto an aluminum salt,
- adsorbing pertussis toxoid and filamentous hemagglutinin in purified form onto an aluminum salt,
- mixing the components obtained in a) with those obtained in b),
- adding inactivated polio virus,

Subj:

Cont

Subj:

Subj:

e) adding a solution of a conjugate of a carrier molecule selected from tetanus toxoid and diphtheria toxoid and a capsular polysaccharide of *Haemophilus influenzae* type B.

27. A method according to claim 25 wherein mixing is conducted in the following order:

- adsorbing tetanus toxoid and diphtheria onto an aluminum salt,
- adsorbing pertussis toxoid and filamentous hemagglutinin in purified form onto an aluminum salt,
- mixing the components obtained in a) with those obtained in b),
- adding inactivated poliovirus after c),
- adding hepatitis B surface antigen previously adsorbed onto an aluminum salt after d),
- adding a solution of a conjugate of a carrier molecule selected from tetanus toxoid and diphtheria toxoid and a capsular polysaccharide of *Haemophilus influenzae* type B after e).

28. The method according to claim 21, wherein said conjugate of a carrier molecule selected from tetanus toxoid and diphtheria toxoid and a capsular polysaccharide of *Haemophilus influenzae* type B is prepared in a phosphate buffer solution before being mixed with the other components.

29. The method according to claim 25, wherein hepatitis B surface antigen previously adsorbed onto aluminum salt is added separately from the other components within a dual chamber syringe.

Sub. FD

Q1

Cont

30. A multi-component vaccine obtained by the method according to claim 21.

31. The multi-component vaccine according to claim 30, wherein the amounts of pertussis toxoid and filamentous hemagglutinin are between 5 and 30 µg in a single dose of said multi-component vaccine.

32. The multi-component vaccine according to claim 30, wherein the amounts of diphtheria toxoid and tetanus toxoid are between 5 and 30 LF in a single dose of said multi-component vaccine.

33. The multi-component vaccine according to claim 30 wherein the amounts of the different polioviruses are

- a) between 20 and 50 D antigen units of poliovirus type1,
- b) between 4 and 10 D antigen units of poliovirus type2, and
- c) between 8 and 40 antigen units of poliovirus type3,

in a single dose of said multi-component vaccine.

34. A multi-component vaccine according to claim 10 wherein the composition of said vaccine comprises per 0.5 ml dose:

- a) 25 µg pertussis toxoid;
- b) 25 µg filamentous hemagglutinin;
- c) 30 LF diphtheria toxoid;
- d) 10 Lf tetanus toxoid;
- e) 40 D antigen units poliovirus type 1;
- f) 8 D antigen units poliovirus type 2;

cont

- g) 32 D antigen units poliovirus type 3;
- h) 10 μ g Haemophilus influenzae type B polysaccharide covalently bound to 20 μ g tetanus toxoid;
- i) 5 μ g hepatitis B surface antigen;
- j) 20 μ Moles phosphates;
- k) 5 μ Moles carbonates;
- l) 0.125 ml of 50 mM tris buffer; and
- m) 0.306 mg aluminum salt.

35. The multi-component vaccine according to claim 30, wherein the composition of said

vaccine comprises per 0.5 ml dose:

- a) 25 μ g pertussis toxoid;
- b) 25 μ g filamentous hemagglutinin;
- c) 30 LF diphtheria toxoid;
- d) 10 Lf tetanus toxoid;
- e) 40 D antigen units poliovirus type 1;
- f) 8 D antigen units poliovirus type 2;
- g) 32 D antigen units poliovirus type 3;
- h) 10 μ g Haemophilus influenzae type B polysaccharide covalently bound to 20 μ g tetanus toxoid;
- i) 5 μ g hepatitis B surface antigen;
- j) 20 μ Moles phosphates;
- k) 5 μ Moles carbonates;